Bullous Pemphigoid Associated with Nivolumab, a Programmed Cell Death 1 Protein Inhibitor

Abstract

Checkpoint inhibitors, such as nivolumab, are revolutionary new drugs in cancer therapy. Mild dermatologic toxicities are commonly reported adverse events. Herein, we highlight the development of the autoimmune blistering condition, bullous pemphigoid (BP) in a patient undergoing treatment with nivolumab.

A 60-year-old man, who was being treated with nivolumab (3mg/kg intravenously every 2 weeks) after failing chemotherapy for metastatic renal cell carcinoma, presented acutely with a blistering rash.

This article is protected by copyright. All rights reserved.

http://ift.tt/2jezZiY